In short
Clinical trials of Anitocabtagene Autoleucel are studying its use in multiple myeloma, a cancer of plasma cells in the bone marrow. The trials are looking at safety, response rates, and disease control in people with newly diagnosed or relapsed/refractory disease. They include Phase 2 and Phase 3 studies in adults who meet specific prior-treatment criteria.
Key points
- Clinical trials of Anitocabtagene Autoleucel are studying multiple myeloma in two main settings: newly diagnosed disease and relapsed/refractory disease. One study is Phase 2 and focuses on safety and early efficacy after induction therapy, while the other is Phase 3 and compares the treatment with standard of care. The target groups are adults with newly diagnosed multiple myeloma and adults who have already received 1 to 3 prior treatments for relapsed/refractory disease. Main outcomes include adverse events, complete response, minimal residual disease negativity, and progression-free survival. Both trials are listed as authorised. The studies are designed to learn how well Anitocabtagene Autoleucel works and how safe it is in these patient groups.
Trials overview
Two interventional studies are investigating Anitocabtagene Autoleucel in multiple myeloma, which is a cancer of plasma cells in the bone marrow. One study is in people with newly diagnosed disease, and the other is in people with relapsed/refractory disease, meaning the cancer came back or did not respond well to earlier treatment. The studies are listed as authorised.
Phase 2 study in newly diagnosed multiple myeloma
The first trial is a Phase 2, open-label study in participants with newly diagnosed multiple myeloma according to IMWG criteria. Open-label means everyone in the study knows which treatment is being given. This study aims to evaluate the safety and efficacy of Anitocabtagene Autoleucel after induction therapy, which means treatment given before the main study therapy.
The brief summary says the study is designed to characterize safety after induction therapy and to further characterize the efficacy profile in this newly diagnosed group. The planned enrollment is 30 participants.
Phase 3 study in relapsed/refractory multiple myeloma
The second trial is a Phase 3 study comparing Anitocabtagene Autoleucel with standard of care therapy in participants with relapsed/refractory multiple myeloma. This study is larger and is meant to compare how well the treatment works against usual treatment options. It includes patients who have had 1 to 3 prior lines of therapy and have been exposed to both an immunomodulatory drug and an anti-CD38 monoclonal antibody.
The brief summary states that the study will compare the efficacy of Anitocabtagene Autoleucel versus standard of care therapy in relapsed/refractory multiple myeloma. The planned enrollment is 642 participants.
Who can participate
Eligibility is different for each trial. In the Phase 2 study, participants must have newly diagnosed multiple myeloma according to IMWG criteria. In the Phase 3 study, participants must have relapsed/refractory multiple myeloma, 1 to 3 prior treatment lines, and prior exposure to both an immunomodulatory drug and an anti-CD38 monoclonal antibody.
- Newly diagnosed group: people whose multiple myeloma has just been found and who meet IMWG diagnostic rules.
- Relapsed/refractory group: people whose disease returned after treatment or did not respond well enough, and who already received several prior therapies.
What the trials measure
The Phase 2 study measures the incidence, seriousness, and severity of all adverse events, which are medical problems that happen during a study. It also measures the rate of uMRD negative complete response at 12 months, with a small allowed time window of plus or minus 3 months after enrollment. uMRD means undetectable minimal residual disease, so this endpoint checks whether no tiny signs of disease can be found by the study test level used in the trial.
The Phase 3 study measures progression-free survival, which is the time until the disease gets worse or death occurs from any cause, whichever happens first. It also measures MRD-negative complete response at 9 months, using bone marrow testing and IMWG response rules assessed by an independent review committee. MRD negativity in this trial means a negative test result at 9 months, with a small allowed time window of plus or minus 3 months.
- Adverse events: unwanted medical problems that happen during the study.
- Complete response: a strong treatment result where disease is not found by the study rules.
- Bone marrow assessment: a test of the soft tissue inside bones where myeloma cells are found.
- Independent review committee (IRC): a separate group that checks study results in a fair way.
Trial status and size
Both studies are listed as authorised, meaning they have been approved to proceed in the provided trial data. The Phase 2 study plans to enroll 30 participants, while the Phase 3 study plans to enroll 642 participants. The difference in size fits the different goals of the studies: early safety and response checking in a smaller group, and comparison with standard care in a larger group.